Founded in 2018, InxMed is a clinical-stage oncology focused biotech company with a winning strategy of “Best-in-Disease Combination”. With disease biology being the source of innovation, the company aims to find solutions for oncology drug resistance and tumor metastasis, especially resistance to anti-PD-1. We are dedicated to researching the tumor microenvironment and building a distinct translational medicine platform with strong proof-of-concept validation capability. We aspire to become a China-based company with global impact.
We have established translational medicine and clinical teams at Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada and Australia. We have built up a novel and highly differentiable pipeline with intrinsic synergy through collaboration with partners, licensing-in, and independent discovery research and development. Our pipeline contains “First-in-Class NME” and “Best-in-Disease Combination” medicines, which enables InxMed to have significant impact on select types of tumors. InxMed prides itself on partnerships with well-known multinational pharmaceutical companies including Roche, Boehringer Ingelheim, and MSD, as well as many Chinese and global biotech companies. We always actively seek opportunities for collaboration with the goal to benefit patients.
InxMed management team members had senior R&D and commercial positions in top-ranking multinational companies, such as Roche, Novartis, MSD, Schering-Plough, GlaxoSmithKline, Johnson & Johnson and BeiGene. They have experience in leadingover a dozen of clinical development programs and new drug applications in China, including products such as Keytruda and Gardasil. They are experts in all aspects of innovative drug research, development, clinical translation, proof-of-concept validation, and marketing.